Professor Robin Shattock, of St George’s, University of London, who will coordinate the research network called “EUROPRISE”, said the award held out the promise of “the most important advance yet in scientific efforts at a European-wide level in HIV-1 prevention and represents another resounding endorsement of the high commitment to HIV/AIDS prevention research in Europe”.
The European HIV Enterprise (EUROPRISE) consortium will promote an integrated programme of research, coordinating a the European portfolio of activities, encompassing the whole pipeline of vaccine and microbicide development from early discovery through to early clinical trials for the next five years. Through their existing partners, the thirty-two funded institutions will bring in a wide network of 150 institutions from 22 countries to the consortium. This unique approach places the network at the international forefront of understanding the interface between these two technologies (microbicides and vaccines), pursuing a critical path to the development of effective HIV-1 prevention strategies.
The urgent need for HIV prevention
The UNAIDS/WHO estimates that at the end of 2004, forty million people globally were living with HIV, of which 610,000 were in Western Europe and 28.5 million were in Sub-Saharan Africa. Globally, there are 14,000 new HIV infections per day, 80% of which are now heterosexual, and 95% of which are in developing countries. In some countries, public health programmes encouraging the use of condoms have achieved modest results in reducing HIV infection rates but it is clear that other preventative strategies are needed. “Although therapeutics for HIV/AIDS continue to improve, ultimately the development of safe and effective strategies of blocking and preventing HIV transmission will be key to combating this pandemic”, says Professor Shattock.
Why Microbicides and Vaccines?
It is currently understood that conventional vaccine approaches fail to induce sufficient mucosal response and immunological memory to provide protection against the diversity of circulating HIV strains. In contrast, while it may be technically easier to develop microbicides (vaginal formulation, gels or creams) that prevent HIV transmission, their duration of protection is likely to be short lived and their efficacy will be critically dependent upon consistent use. In the past, both fields have been slow to work together in the development of products that provide multiple levels of protection. This network is focused on the premise that microbicides and vaccines that target multiple stages of mucosal transmission will have the best chance of success. Since both target the same processes there is clear overlap between the two fields.
What is the timescale and who is involved
St George’s, University of London was chosen to coordinate the consortium due to its expertise on HIV/AIDS research, together with the scientific coordination Hans Wigzell from the Karolinska Institutet (Stockholm) and Rino Rappuoli, the coordinator for HIV vaccines, from Novartis (Siena). In despite of the UK, Italy and Sweden, the other countries involved are Austria, Belgium, France, Germany, Netherlands, Russia and Spain.
This is a five-year project that will start on January 1st 2007 and is designed to take this approach into early human trials.
Andrea Vazquez | alfa
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.
Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
02.12.2016 | Medical Engineering
02.12.2016 | Agricultural and Forestry Science
02.12.2016 | Physics and Astronomy